Literature DB >> 27649046

MnTBAP Inhibits Bleomycin-Induced Pulmonary Fibrosis by Regulating VEGF and Wnt Signaling.

Rajkumar Venkatadri1, Anand Krishnan V Iyer1, Vani Ramesh2, Clayton Wright1, Carlos A Castro3, Juan S Yakisich1, Neelam Azad1.   

Abstract

Cellular oxidative stress is implicated not only in lung injury but also in contributing to the development of pulmonary fibrosis. We demonstrate that a cell-permeable superoxide dismutase (SOD) mimetic and peroxynitrite scavenger, manganese (III) tetrakis (4-benzoic acid) porphyrin chloride (MnTBAP) significantly inhibited bleomycin-induced fibrogenic effects both in vitro and in vivo. Further investigation into the underlying mechanisms revealed that MnTBAP targets canonical Wnt and non-canonical Wnt/Ca2+ signaling pathways, both of which were upregulated by bleomycin treatment. The effect of MnTBAP on canonical Wnt signaling was significant in vivo but inconclusive in vitro and the non-canonical Wnt/Ca2+ signaling pathway was observed to be the predominant pathway regulated by MnTBAP in bleomycin-induced pulmonary fibrosis. Furthermore, we show that the inhibitory effects of MnTBAP involve regulation of VEGF which is upstream of the Wnt signaling pathway. Overall, the data show that the superoxide scavenger MnTBAP attenuates bleomycin-induced pulmonary fibrosis by targeting VEGF and Wnt signaling pathways. J. Cell. Physiol. 232: 506-516, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27649046      PMCID: PMC5662016          DOI: 10.1002/jcp.25608

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  60 in total

1.  A proteomics approach to identifying key protein targets involved in VEGF inhibitor mediated attenuation of bleomycin-induced pulmonary fibrosis.

Authors:  Yogesh M Kulkarni; Sucharita Dutta; Anand Krishnan V Iyer; Rajkumar Venkatadri; Vivek Kaushik; Vani Ramesh; Clayton A Wright; Oliver John Semmes; Juan S Yakisich; Neelam Azad
Journal:  Proteomics       Date:  2015-11-24       Impact factor: 3.984

2.  WNT/β-catenin signaling induces IL-1β expression by alveolar epithelial cells in pulmonary fibrosis.

Authors:  Verena Aumiller; Nisha Balsara; Jochen Wilhelm; Andreas Günther; Melanie Königshoff
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

3.  The mechanism of endogenous receptor activation functionally distinguishes prototype canonical and noncanonical Wnts.

Authors:  Guizhong Liu; Anna Bafico; Stuart A Aaronson
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

4.  Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis.

Authors:  Thong Hua-Huy; Nhat-Nam Le-Dong; Sy Duong-Quy; Yihua Bei; Sébastien Rivière; Kiet-Phong Tiev; Carole Nicco; Christiane Chéreau; Frédéric Batteux; Anh Tuan Dinh-Xuan
Journal:  J Breath Res       Date:  2015-06-16       Impact factor: 3.262

Review 5.  Protein kinase C in Wnt signaling: implications in cancer initiation and progression.

Authors:  Luis Bernardo Luna-Ulloa; José G Hernández-Maqueda; M Cristina Castañeda-Patlán; Martha Robles-Flores
Journal:  IUBMB Life       Date:  2011-09-09       Impact factor: 3.885

6.  The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway.

Authors:  Isao Oishi; Hiroaki Suzuki; Nobuyuki Onishi; Ritsuko Takada; Shuichi Kani; Bisei Ohkawara; Ikue Koshida; Kentaro Suzuki; General Yamada; Georg C Schwabe; Stefan Mundlos; Hiroshi Shibuya; Shinji Takada; Yasuhiro Minami
Journal:  Genes Cells       Date:  2003-07       Impact factor: 1.891

Review 7.  Noncanonical Wnt signaling in tumor progression and metastasis.

Authors:  Jason R Jessen
Journal:  Zebrafish       Date:  2009-03       Impact factor: 1.985

8.  Transcriptional regulation of increased CCL2 expression in pulmonary fibrosis involves nuclear factor-κB and activator protein-1.

Authors:  Xiaoling Deng; Mingyan Xu; Chao Yuan; Liqin Yin; Xihe Chen; Xiaoqiong Zhou; Guanwu Li; Yucai Fu; Carol A Feghali-Bostwick; Linhua Pang
Journal:  Int J Biochem Cell Biol       Date:  2013-04-10       Impact factor: 5.085

9.  PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation.

Authors:  Anna R Hemnes; Ari Zaiman; Hunter C Champion
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-10-26       Impact factor: 5.464

Review 10.  Studies on free radicals, antioxidants, and co-factors.

Authors:  Khalid Rahman
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more
  9 in total

1.  RGMa Participates in the Blood-Brain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis.

Authors:  Lei Zhang; Shi Tang; Yue Ma; Junhang Liu; Philippe Monnier; Hang Li; Rongrong Zhang; Gang Yu; Mengjie Zhang; Yongmei Li; Jinzhou Feng; Xinyue Qin
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

2.  A Single-Cell Network-Based Drug Repositioning Strategy for Post-COVID-19 Pulmonary Fibrosis.

Authors:  Albert Li; Jhih-Yu Chen; Chia-Lang Hsu; Yen-Jen Oyang; Hsuan-Cheng Huang; Hsueh-Fen Juan
Journal:  Pharmaceutics       Date:  2022-04-30       Impact factor: 6.525

3.  Radiation-Mediated Tumor Growth Inhibition Is Significantly Enhanced with Redox-Active Compounds That Cycle with Ascorbate.

Authors:  Artak Tovmasyan; Jacqueline C Bueno-Janice; Melba C Jaramillo; Romulo S Sampaio; Julio S Reboucas; Natalia Kyui; Ludmil Benov; Brian Deng; Ting-Ting Huang; Margaret E Tome; Ivan Spasojevic; Ines Batinic-Haberle
Journal:  Antioxid Redox Signal       Date:  2018-03-27       Impact factor: 8.401

4.  MnTBAP inhibits bone loss in ovariectomized rats by reducing mitochondrial oxidative stress in osteoblasts.

Authors:  Xiangchang Cao; Deqing Luo; Teng Li; Zunxian Huang; Weitao Zou; Lei Wang; Kejian Lian; Dasheng Lin
Journal:  J Bone Miner Metab       Date:  2019-09-06       Impact factor: 2.626

Review 5.  Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression.

Authors:  David M Dolivo; Sara A Larson; Tanja Dominko
Journal:  Cytokine Growth Factor Rev       Date:  2017-09-23       Impact factor: 7.638

Review 6.  Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis.

Authors:  Cristina Estornut; Javier Milara; María Amparo Bayarri; Nada Belhadj; Julio Cortijo
Journal:  Front Pharmacol       Date:  2022-01-21       Impact factor: 5.810

7.  MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.

Authors:  Maria Catalina Gomez-Puerto; Xiao-Qing Sun; Ingrid Schalij; Mar Orriols; Xiaoke Pan; Robert Szulcek; Marie-José Goumans; Harm-Jan Bogaard; Qian Zhou; Peter Ten Dijke
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

8.  MiR-503 suppresses fibroblast activation and myofibroblast differentiation by targeting VEGFA and FGFR1 in silica-induced pulmonary fibrosis.

Authors:  Qiuyun Wu; Lei Han; Wenwen Gui; Feng Wang; Weiwen Yan; Hua Jiang
Journal:  J Cell Mol Med       Date:  2020-11-01       Impact factor: 5.295

9.  Bioinformatics Analysis Identifies Potential Ferroptosis Key Genes in the Pathogenesis of Pulmonary Fibrosis.

Authors:  Jie He; Xiaoyan Li; Mi Yu
Journal:  Front Genet       Date:  2022-01-06       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.